CN107056959A - Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation - Google Patents
Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation Download PDFInfo
- Publication number
- CN107056959A CN107056959A CN201710080999.9A CN201710080999A CN107056959A CN 107056959 A CN107056959 A CN 107056959A CN 201710080999 A CN201710080999 A CN 201710080999A CN 107056959 A CN107056959 A CN 107056959A
- Authority
- CN
- China
- Prior art keywords
- jerusalem artichoke
- active ingredient
- rsv
- virus
- antiviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008892 Helianthus tuberosus Species 0.000 title claims abstract description 34
- 235000003230 Helianthus tuberosus Nutrition 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 13
- 238000000926 separation method Methods 0.000 claims abstract description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001556 precipitation Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 10
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 10
- 239000005017 polysaccharide Substances 0.000 claims abstract description 10
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract description 9
- 230000003602 anti-herpes Effects 0.000 claims abstract description 9
- 239000012535 impurity Substances 0.000 claims abstract description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003208 petroleum Substances 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 4
- 238000010992 reflux Methods 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 238000009395 breeding Methods 0.000 claims description 3
- 230000001488 breeding effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 230000002155 anti-virotic effect Effects 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 11
- 241000700584 Simplexvirus Species 0.000 abstract description 6
- 230000003612 virological effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000709661 Enterovirus Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Sustainable Development (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to active ingredient of Chinese herbs production extraction process and active ingredient identification field, it is related to the new technology and the new application in pharmaceutical field of identification and the extracts active ingredients separation of the viral active ingredient of the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), enteron aisle EV 71, and in particular to extracted using the mode of antiviral tracking and prepare the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of the viruses of enteron aisle EV 71.Specific steps include water refluxing extraction jerusalem artichoke, alcohol precipitation, it is antiviral, dissolving precipitation, soda acid removal of impurities, petroleum ether are except oil-soluble impurities, Sevag methods de- albumen, activated carbon decolorizing, white solid is finally freeze-dried to obtain, molisch reactions and antiviral study in vitro is carried out, it is jerusalem artichoke polysaccharide to determine active ingredient.The viral active ingredient of jerusalem artichoke moderate resistance herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV 71, the features such as it has safe as natural extract are found that present invention employs the method for antiviral tracking.
Description
Technical field
The present invention relates to active ingredient of Chinese herbs production extraction process and active ingredient identification field, it is related to jerusalem artichoke antiviral
New approaches new method and the new application in pharmaceutical field that active component is extracted, and in particular to utilize the mode of antiviral tracking
The type virus of extraction separation and purification jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses.
Background technology
All receive various viral invasions all over the world since the last few years, such as SARS virus, H1N1 etc., often
Secondary viral outburst can all cause the panic and death of the mankind.So it is extremely urgent to find suitable antiviral drugs.
Herpes simplex virus can cause a variety of diseases of the mankind, such as gingivostomatitis, keratoconjunctivitis, encephalitis and system genitale togetherness
Dye and neonatal infection.After infection host, latent infection is often set up in nerve cell, is occurred again after activation asymptomatic
Toxin expelling, propagation chain is maintained in crowd, the circulation gone round and begun again.
Respiratory Syncytial Virus(RSV) is to cause one of most important pathogen of infant's acute lower respiratory infection, can there is height
Heat, rhinitis, pharyngitis and laryngitis, show as capillary bronchitis and pneumonia later.A small number of sick children can concurrently tympanitis, pleurisy and the heart
Myositis etc..After adult and older children infect, the infection of the upper respiratory tract is mainly shown as, can also cause interstitial pneumonia and capillary branch
Tracheitis etc. can also cause the elderly and immune deficiency patient to be in hospital and pneumonia death simultaneously.
The enterovirus group that enterovirus belongs in virology in Parvoviridae, EV-71 be in current enterovirus group most
The virus that evening finds, its infectious pole and it is strong and pathogenicity rate is higher, the complication especially in terms of nervous system.EV-71
Virus is to cause one of main pathogens of Children, can also cause aseptic meningitis, BBE and spinal cord
A variety of the nervous system diseases such as the paralysis of poliomyelitis sample.
Jerusalem artichoke is commonly called as Jerusalem artichoke, Jerusalem artichoke, belongs to composite family Compositac, is that a kind of Helianthus perennial root draft is planted
Thing, jerusalem artichoke typically yields positive results in the fall, and this flower-shape is like chrysanthemum, and edible part is generally the stem tuber grown in stem tuber, soil and is rich in
The Multiple components such as many sugar and starches, jerusalem artichoke has anti-oxidant, anticancer, antibacterium and antimycotic isoreactivity, can be used as antipyretic, town
Bitterly, anti-inflammatory and antitetanic drug therapy fracture, swelling, skin trauma and pain etc..
Jerusalem artichoke has certain therapeutic action to herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses,
Experiment shows that the active ingredient that jerusalem artichoke is extracted has very to herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses
Good therapeutic action.
The content of the invention
The technical problems to be solved by the invention be specify that the type virus of jerusalem artichoke anti-herpes simplex I, Respiratory Syncytial Virus(RSV),
The active ingredient of enteron aisle EV-71 viruses, and provide a kind of side using antiviral tracking for the separation and Extraction of the active ingredient
Formula prepares the new method of the antiviral active ingredient of jerusalem artichoke.The active ingredient extracts isolated from feverfew plant jerusalem artichoke
It can be used for herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), the treatment of enteron aisle EV-71 virus infection.This method can be more
Easy carries out separation and Extraction to above active ingredient.
It is an advantage of the invention that the present invention has been isolated in jerusalem artichoke first there is the type of anti-herpes simplex I virus, respiratory tract to close
A kind of active ingredient of cellular virus, enteron aisle EV-71 viruses, and invented a kind of method of antiviral tracking the active ingredient is entered
Preparation is gone, this separation method purpose is strong, simply saves substantial amounts of manpower and materials, has been separated better than traditional system.Prepare
Obtained active ingredient there is preferably treatment to make herpes simplex virus Ⅰ, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 viruses
With.
The type virus of jerusalem artichoke anti-herpes simplex I of the present invention, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses are
Jerusalem artichoke polysaccharide, the preparation method of the active ingredient, comprises the following steps：
（1）Take a certain amount of jerusalem artichoke medicinal material 10 times of water heating and refluxing extraction 2 times, 2 hours for the first time, second 1.5 hours；
（2）The extract solution merged twice is concentrated under reduced pressure, and is concentrated into the medicinal material that every milliliter of decoction contains 1 gram, then adds ethanol regulation
The concentration of ethanol is, 80%, stand 48 hours.It is filtrated to get precipitation and supernatant；
（3）Supernatant is reclaimed into ethanol, precipitation water is dissolved, Antiviral breeding is carried out respectively.It is disease-resistant that experiment display is precipitated
Toxic effect fruit is preferable；
（4）Under agitation, milk of lime is slowly instilled into precipitation lysate, regulation pH value to 11.0 stands in a moment, is put into 80
1 h is incubated in DEG C water-bath, suction filtration removes insoluble matter, collects filtrate；Phosphoric acid is slowly dropped into filtrate, and is stirred continuously, is adjusted
PH value is saved to 8.0, is separated with centrifuge (4000 r/min, 15 min), collects centrifugate；
（5）The petroleum ether of 10 times of amounts is added into centrifugate, is extracted with separatory funnel, stratification, upper strata is petroleum ether layer, under
Layer is water layer, collects lower floor, is repeated 3 times, and removes oil-soluble impurities；
（6）Protein in extract solution, extract solution are removed using Sevag methods：Sevag reagent=5:1（v/v）, Sevag reagents are
Chloroform：N-butanol=5:1（v/v）.Chloroform and n-butanol are well mixed, are poured slowly into the case where being stirred continuously equipped with extract solution
In beaker, preservative film sealing, with the min of magnetic stirrer 40, is poured into separatory funnel, static layering.3 layers of liquid point, on
Layer is extraction liquid layer, and intermediate layer is denatured protein layer, and lower floor is Sevag reagent layers, collects upper solution, and centrifuge out
A small amount of denatured protein, is repeated 5 times by above-mentioned steps, makes the removal of protein in extract solution complete；
（7）Weigh activated carbon（Consumption is 5 g/L）Pour into extract solution, after stirring, be put in 80 DEG C of thermostat water baths and protect
30 min of temperature, suction filtration, room temperature is cooled to by filtrate while hot；
（8）Extract solution is poured into refrigerator tray, and is put in refrigerator and freezes 24 h, freeze it is solid after be put in freeze drier and do
It is dry, it is dried after powder is fitted into labelled standby in ep pipes；
（9）Will（8）Obtained powder carries out molisch reactions, is as a result positive, and it is jerusalem artichoke polysaccharide to determine the composition；
（10）Will（8）Obtained powder dissolving carries out antiviral study in vitro, and it is anti-well that experimental result shows that jerusalem artichoke polysaccharide has
Virus effectiveness.
Embodiment
Example 1（1）Weigh a certain amount of jerusalem artichoke plus 10 times of amount heating and refluxing extractions twice, 2 hours for the first time, second
1.5 hours, merge extract solution twice, be concentrated under reduced pressure into the medicinal material that every milliliter of decoction contains 1 gram, plus ethanol adjusts solution ethanol
Concentration is 80%, stands 48 hours.
（2）Will（1）Obtained precipitation solution decompression suction filtration, is precipitated, by precipitation distilled water ultrasonic dissolution.
（3）Will（2）Obtained solution carries out soda acid removal of impurities, petroleum ether except oil-soluble impurities, Sevag methods take off albumen, activity
Carbon decoloring, is finally freeze-dried to obtain white solid.
（4）Will（3）In obtained white powder carry out molisch reactions and antiviral study in vitro, experimental result is shown
Its type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), enteron aisle EV-71 virus effectiveness are preferable.
Claims (10)
1. there is the type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses in a kind of jerusalem artichoke
With a kind of process of the mode extraction separation and purification active ingredient using antiviral tracking, it is characterised in that this effectively into
It is divided into jerusalem artichoke polysaccharide.
2. first with water extract-alcohol precipitation, soda acid removal of impurities, petroleum ether are then carried out except oil-soluble impurities, Sevag methods take off albumen, activity
Carbon decoloring, is finally freeze-dried to obtain white solid, and jerusalem artichoke polysaccharide is accredited as through molisch reactions.
3. active ingredient according to claim 1 is characterized in that the active ingredient is jerusalem artichoke polysaccharide.
4. extraction separation method according to claim 1, it is characterised in that the solid-liquid ratio of jerusalem artichoke water refluxing extraction is 1：10, carry
Take number of times twice, extraction time is 2 hours for the first time, second 1.5 hours.
5. extraction separation method according to claim 1, it is characterised in that the concentrate concentration of Aqueous extracts is that 1ml decoctions contain
1g medicinal material, alcohol precipitation concentration is 80%, and the alcohol precipitation time is 48 hours.
6. extraction separation method according to claim 1, it is characterised in that decompression suction filtration is carried out after alcohol precipitation, obtain precipitation and
Supernatant, then carries out Antiviral breeding and obtains being precipitated as antivirus effective position.
7. extraction separation method according to claim 1, it is characterised in that carry out soda acid removal of impurities with sodium hydroxide and phosphoric acid, so
Remove oil-soluble impurities with petroleum ether again afterwards.
8. extraction separation method according to claim 1, it is characterised in that take off albumen with Sevag methods and use activated carbon decolorizing,
Finally it is freeze-dried to obtain white solid.
9. extraction separation method according to claim 1, it is characterised in that molisch reactions are the positive, identify this effectively into
It is divided into and is divided into jerusalem artichoke polysaccharide.
10. extraction separation method according to claim 1, it is characterised in that jerusalem artichoke polysaccharide is subjected to Antiviral breeding, obtained
Jerusalem artichoke polysaccharide is the type virus of anti-herpes simplex I, Respiratory Syncytial Virus(RSV), the active ingredient of enteron aisle EV-71 viruses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080999.9A CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080999.9A CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107056959A true CN107056959A (en) | 2017-08-18 |
Family
ID=59598603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710080999.9A Pending CN107056959A (en) | 2017-02-15 | 2017-02-15 | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107056959A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346086A (en) * | 2020-04-30 | 2020-06-30 | 鲁东大学 | Application of compound in preparation of antiviral drug |
| CN112841229A (en) * | 2021-01-27 | 2021-05-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101731509A (en) * | 2008-11-20 | 2010-06-16 | 郝琳琳 | Method for extracting inulin from Canada potato |
| CN103141383A (en) * | 2013-02-28 | 2013-06-12 | 王茜 | Method for producing jerusalem artichoke by tissue culture technology |
| CN104366195A (en) * | 2014-11-27 | 2015-02-25 | 高铭鸿 | Intestinal probiotics and Jerusalem artichokes polysaccharide tablets |
| CN105287722A (en) * | 2015-08-27 | 2016-02-03 | 李宏 | Danshen root-Jerusalem artichoke polysaccharide tablet |
-
2017
- 2017-02-15 CN CN201710080999.9A patent/CN107056959A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101731509A (en) * | 2008-11-20 | 2010-06-16 | 郝琳琳 | Method for extracting inulin from Canada potato |
| CN103141383A (en) * | 2013-02-28 | 2013-06-12 | 王茜 | Method for producing jerusalem artichoke by tissue culture technology |
| CN104366195A (en) * | 2014-11-27 | 2015-02-25 | 高铭鸿 | Intestinal probiotics and Jerusalem artichokes polysaccharide tablets |
| CN105287722A (en) * | 2015-08-27 | 2016-02-03 | 李宏 | Danshen root-Jerusalem artichoke polysaccharide tablet |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346086A (en) * | 2020-04-30 | 2020-06-30 | 鲁东大学 | Application of compound in preparation of antiviral drug |
| CN111346086B (en) * | 2020-04-30 | 2022-10-21 | 鲁东大学 | Application of a compound in the preparation of antiviral drugs |
| CN112841229A (en) * | 2021-01-27 | 2021-05-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
| CN112841229B (en) * | 2021-01-27 | 2021-12-28 | 烟台恩倍得化工科技有限公司 | Composition containing jerusalem artichoke leaf extracting solution and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102114044B (en) | Artificially processed bear bile powder and preparation method thereof | |
| CN106668657A (en) | Beverage capable of lowering uric acid and lipid and preparation method of beverage | |
| CN102008076B (en) | Egg albumen nutrition mixture beneficial to adjustment of immune function and preparation method thereof | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN104367987B (en) | Formulation of astragalus root for animals and preparation method thereof | |
| CN103405639B (en) | Phellinus igniarius polyose and traditional Chinese medicine compound blood-glucose lowering oral liquid and preparation method thereof | |
| CN105326880A (en) | Rape pollen water soluble extract as well as preparation method and application thereof | |
| CN104306399B (en) | A kind of deer spleen extract extracting method and the application in immunity medicine is improved | |
| CN103564495B (en) | Propolis and cordycepic hypha powder composition, as well as preparation and application thereof | |
| CN109601795A (en) | Composition hangover drink with yellow grass as main raw material and preparation method thereof | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN106138101B (en) | A kind of preparation method of chicken embryo placenta extract | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN104288344A (en) | Applications of a Pu'er tea extract product in preparation of medicines or foods adjusting intestinal flora and relaxing the bowels | |
| CN105687036A (en) | Rhizoma bletillae skin care product and method for preparing same | |
| CN111840349B (en) | Method for simultaneously extracting polysaccharide and flavonoid components from folium artemisiae argyi | |
| CN102150828B (en) | Fig preparation for nourishing and protecting liver | |
| CN102283859A (en) | Application of dicliptera chinensis polysaccharide | |
| WO2016141774A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for improving and enhancing sexual function | |
| CN104403020A (en) | Semi-bionic lentinan extraction method | |
| CN105483160B (en) | A kind of Antrodia camphorata culture composition and preparation method thereof | |
| CN102816226A (en) | Preparation method of porcine small intestine antibacterial peptides PR39 | |
| CN102861333B (en) | High-activity composite antibody oral preparation for resisting bursa fabricius viruses and influenza viruses of chicken | |
| CN105533737A (en) | Black garlic oral liquid containing wormwood leaf extract as well as preparation method and usage thereof | |
| TWI618540B (en) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |